VC firms
Invivo Capital Partners
Edit

Invivo Capital Partners

https://invivo.capital/
Last activity: 22.06.2023
Probably Closed
Invivo Capital Partners promoted by Albert Ferrer and Lluís Pareras, is a management company investing in early stages companies in the healthcare sector. Invivo Capital Partners has a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. It also has a network of contacts and key strategic relationships in the health ecosystem. Invivo Ventures is managed by Invivo Capital Partners, promoted by Luis Pareras and Albert Ferrer, with the experience gained through the first fund Healthequity. The fund was registered to the Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and has achieved a final closing of 60M €. We are a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. We also have a network of contacts and key strategic relationships in the health ecosystem. Our company is financed by the European Investment Fund, the Instituto de Crédito Oficial, the Institut Català de Finances, the Institut Valencià de Finances, the Ajuntament de Barcelona and other private investors. Two successful exits from our first fund in 2022, validating our early-stage investment thesis focused on extraordinary science in leading-edge fields that are to play a role in the future of medicine. Our portfolio companies from the first fund have raised >220M€ from international VCs. Our knowledge of the Technology Transfer space plus our ability to identify new market trends and create biotech companies opens the opportunity to become one of the major players in Technology Transfer in Europe.
Followers
2.15K
Portfolio
1
Mentions
15

Overview

Location
Spain, Catalonia, Barcelona
Employees
1-10
Founded date
2019
Investment Type
Venture Capital
Investment Stage
Pre-Seed; Seed; Series A

Portfolio 1

DateNameWebsiteTotal RaisedLocation
Sign up to seeSign up to seeSign up to seeSign up to seeSign up to see

Mentions in press and media 15

DateTitleDescription
Sign up to seeSign up to seeSign up to see
May 4, 2023ARTHEx Biotech announces Closing of €42M Series B round led by Columbus. EIC), Hadean, Sound Bioventures, Invivo, AdBio and CDTI also participated04/05/2023 Nota de prensa ARTHEX BIOTECH ANNOUNCES CLOSING OF €42M SERIES B ROUND LED BY COLUMBUS. EIC), HADEAN, SOUND BIOVENTURES, INVIVO, ADBIO AND CDTI ALSO PARTICIPATED ARTHEx Biotech S.L., a clinical-stage biotechnology company focu...
Dec 15, 2022Pulmobiotics, participada por Invivo, recibe €1,9M para desarrollar una píldora viva para el cáncer de pulmón15/12/2022 Nota de prensa PULMOBIOTICS, PARTICIPADA POR INVIVO, RECIBE €1,9M PARA DESARROLLAR UNA PÍLDORA VIVA PARA EL CÁNCER DE PULMÓN El equipo científico de Pulmobiotics, una empresa fundada en 2020 en el Centro de Regulación Genómica...
Dec 2, 2021Integra Tx secures €4.5M in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures02/12/2021 Press release INTEGRA TX SECURES €4.5 MILLION IN FUNDING FROM ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL AND TAKEDA VENTURES. The biotechnology company, which specialises in gene editing and was founded by researchers Marc Gü...
Dec 2, 2021Integra Tx cierra una ronda de €4,5M a la que han acudido Advent France Biotechnology, Invivo Capital y Takeda Ventures02/12/2021 Nota de prensa INTEGRA TX CIERRA UNA RONDA DE €4,5M CON ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL Y TAKEDA VENTURES. La biotecnológica, especializada en edición genética y fundada por los investigadores Marc Güell y Avencia ...
May 25, 2021El CDTI invierte junto a Invivo Ventures en la startup biotecnológica Telomere Therapeutics25/05/2021 Nota de prensa EL CDTI INVIERTE JUNTO A INVIVO VENTURES EN TELOMERE THERAPEUTICS, STARTUP BIOTECNOLÓGICA QUE PRETENDE DESARROLLAR NUEVOS TRATAMIENTOS PARA ENFERMEDADES ASOCIADAS A SÍNDROMES TELOMÉRICOS. El CDTI, a través de su...
Mar 8, 2021El Ayuntamiento de Barcelona selecciona a Aldea, 4Founders, Suma Capital, Sabadell Asabys, Invivo y The Extension Fund para canalizar los €10M del Barcelona Acelera08/03/2021 EL AYUNTAMIENTO DE BARCELONA SELECCIONA A ALDEA, 4FOUNDERS, SUMA CAPITAL, SABADELL ASABYS, INVIVO Y THE EXTENSON FUND PARA CANALIZAR LOS €10 MILLONES DEL BARCELONA ACELERA. El Ayuntamiento de Barcelona ya ha seleccionado los fo...
Dec 1, 2020Invivo impulsa la startup de terapia génica Telomere Therapeutics con €1,5M01/12/2020 Nota de prensa INVIVO IMPULSA LA STARTUP DE TERAPIA GÉNICA TELOMERE THERAPEUTICS CON €1,5 MILLONES. Después de varios años de investigaciones y de muchas publicaciones científicas conjuntas, las biólogas moleculares Maria Blas...
Jul 24, 2020Arthex Biotech capta €4,25 millones de Invivo Ventures y Advent France Biotechnology24/07/2020 Nota de prensa ARTHEX BIOTECH CAPTA €4,25 MILLONES DE INVIVO VENTURES Y ADVENT FRANCE BIOTECHNOLOGY. La financiación permitirá a la empresa avanzar en el desarrollo de su terapia para la distrofia miotónica Arthex Biotech (AR...
Jul 24, 2020Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology24/07/2020 Press Release ARTHEX SECURES €4.25M FROM INVIVO VENTURES AND ADVENT FRANCE BIOTECHNOLOGY. Funding will help advance development of company’s Myotonic Dystrophy therapy Arthex Biotech (ARTHEx), a preclinical stage life science...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Invivo Capital Partners

When was Invivo Capital Partners founded?

Invivo Capital Partners was founded in 2019.

How many startups has Invivo Capital Partners invested in?

Invivo Capital Partners has 1 portfolio company on Parsers VC.

What has the press written about Invivo Capital Partners?

Parsers VC has collected 15 articles mentioning Invivo Capital Partners, among them “ARTHEx Biotech announces Closing of €42M Series B round led by Columbus. EIC), Hadean, Sound Bioventures, Invivo, AdBio and CDTI also participated” (May 4, 2023) and “Pulmobiotics, participada por Invivo, recibe €1,9M para desarrollar una píldora viva para el cáncer de pulmón” (Dec 15, 2022).

Is Invivo Capital Partners still active?

Invivo Capital Partners is probably closed: its latest activity on Parsers VC dates from Jun 22, 2023.